10th IAS Conference on HIV Science | 21-24 July 2019 | Mexico City, Mexico

Press releases

New studies and WHO guidance clarify the way forward for use of dolutegravir in women of childbearing age

posted on

22 July 2019 (Mexico City, Mexico) – The safety of the HIV treatment drug, dolutegravir (DTG), during pregnancy has been one of the most urgent questions in global health for the past year.

At the 22nd International AIDS Conference (AIDS 2018) last year, data from the Tsepamo study in Botswana suggested that the use of DTG in early pregnancy may be linked to neural tube defects (NTDs), serious birth defects of the brain and spine.

Continue reading

Sign up for
IAS 2019 news